Upadacitinib
Therapeutic Group
ImmunomodulatorsIndication Dosage
Indication:
Upadacitinib is a Janus kinase (JAK) inhibitor used for:
- Rheumatoid Arthritis (RA) – Joint pain and swelling.
- Psoriatic Arthritis (PsA) – Joint pain with skin issues.
- Ankylosing Spondylitis (AS) – Back and spine pain.
- Non-Radiographic Axial Spondyloarthritis (nr-axSpA) – Spine pain with inflammation.
- Atopic Dermatitis (Eczema) – Severe skin itching and rashes.
- Ulcerative Colitis (UC) & Crohn’s Disease (CD) – Inflammatory bowel diseases.
Dosage:
For Arthritis (RA, PsA, AS, nr-axSpA): 15 mg once daily.
For Severe Eczema (Atopic Dermatitis):
- Adults: 15 mg or 30 mg once daily.
- Children (≥12 years): 15 mg if weight is 40-60 kg, 30 mg if above 60 kg.
For Ulcerative Colitis & Crohn’s Disease:
- Starting dose: 45 mg once daily for 8 weeks.
- After 8 weeks: 15 mg or 30 mg once daily.
Content
- Tab 15mg, 30mg, 45mg: Upadacitinib 15mg, 30mg, 45mg
Pregnancy
Not Recommended
Stability
- Janus Kinase (JAK) Inhibitor
Contra Indications
- Upadacitinib is contraindicated in severe infections (TB, sepsis), liver disease, history of blood clots, severe heart conditions, pregnancy, breastfeeding, and live vaccine use.
Precautions
- Upadacitinib is contraindicated in severe infections (TB, sepsis), liver disease, history of blood clots, severe heart conditions, pregnancy, breastfeeding, and live vaccine use.
Lactation
- Not Recommended
Side Effects
- Infections (TB, herpes, pneumonia)
- Headache
- Nausea
- Fatigue
- Acne
- Increased Liver Enzymes
- High Blood Pressure
- Cough